Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:Expires on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
user
Sign In
Subscribe
ENBM中文TA
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      Indonesia to begin local production of Covid-19 antiviral pills soon
      Malaysiakini
      World
      Indonesia to begin local production of Covid-19 antiviral pills soon

      Indonesia to begin local production of Covid-19 antiviral pills soon

      BernamaPublished: Jan 20, 2022 1:54 AM

      Indonesia is targeting to start local production of two Covid-19 antiviral pills, Molnupiravir and Paxlovid, in April or May this year in order to guarantee the availability of the medicines during the pandemic.

      "The government continues to ensure adequate domestic supply of Covid-19 medicines to anticipate waves of the SARS-CoV-2 virus,” the government's Covid-19 task force spokesperson Reisa Broto Asmoro said at a virtual press conference yesterday...

      Thailand and Indonesia unveil plans to develop molnupiravir Covid-19 pill

      Thailand and Indonesia unveil plans to develop molnupiravir Covid-19 pill

      South Korea authorises emergency use of Pfizer's oral coronavirus treatment

      South Korea authorises emergency use of Pfizer's oral coronavirus treatment

      US authorises Pfizer's antiviral Covid-19 pill

      US authorises Pfizer's antiviral Covid-19 pill

      Omicron forces new restrictions, global call for booster shot

      Omicron forces new restrictions, global call for booster shot

      Pfizer says Covid-19 pill near 90% effective in final analysis

      Pfizer says Covid-19 pill near 90% effective in final analysis

      Pfizer to allow generic versions of its Covid-19 pill in 95 countries

      Pfizer to allow generic versions of its Covid-19 pill in 95 countries

      Bangladesh's Beximco to sell first generic version of Merck Covid-19 pill

      Bangladesh's Beximco to sell first generic version of Merck Covid-19 pill

      Covid-19 pills are coming, but no substitute for vaccines, disease experts say

      Covid-19 pills are coming, but no substitute for vaccines, disease experts say

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports8

      Thailand and Indonesia unveil plans to develop molnupiravir Covid-19 pill

      15-01-2022

      South Korea authorises emergency use of Pfizer's oral coronavirus treatment

      28-12-2021

      US authorises Pfizer's antiviral Covid-19 pill

      23-12-2021

      Omicron forces new restrictions, global call for booster shot

      22-12-2021

      Pfizer says Covid-19 pill near 90% effective in final analysis

      15-12-2021

      Pfizer to allow generic versions of its Covid-19 pill in 95 countries

      16-11-2021

      Bangladesh's Beximco to sell first generic version of Merck Covid-19 pill

      09-11-2021

      Covid-19 pills are coming, but no substitute for vaccines, disease experts say

      09-11-2021
      View Comments0

      Comments0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      NOTICE

      Our commenting system is still under development. We have taken note of feedback provided.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      3200 characters remaining

      Pending comments0

      Are you sure you want to delete this comment?

      This action cannot be undone.

      Report this comment

      500 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor